Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis

Completed · Phase 3 · Has a placebo group

Conditions studied: Blepharoptosis, Synkinesis, Hyperkinesis, Facial Paralysis

In brief

After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment.

Key facts

Study ID

NCT05945615

Run by

Milton S. Hershey Medical Center

People needed

36

Starts

2024-01-11

Expected to finish

2026-01-08

Last updated by the study team

2026-03-09

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Over 18 years of age
• Primary diagnosis of nonflaccid facial paralysis (aberrant regeneration syndrome) and acquired blepharoptosis.

You may not qualify if…

• Patients under the age of 18
• Patients on cardiac glycosides
• Patients on MAO inhibitors
• Patients with angle closure glaucoma
• Patients who experience asymmetrical eye opening due to weakness (e.g. lagophthalmos).

Where it is running

• M.S. Hershey Medical Center — Hershey, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.